Last $34.12 USD
Change Today +1.01 / 3.05%
Volume 1.4M
AKRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

akorn inc (AKRX) Snapshot

Open
$32.73
Previous Close
$33.11
Day High
$34.39
Day Low
$32.09
52 Week High
07/1/14 - $37.08
52 Week Low
07/23/13 - $13.34
Market Cap
3.5B
Average Volume 10 Days
1.5M
EPS TTM
$0.44
Shares Outstanding
103.9M
EX-Date
08/29/91
P/E TM
78.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for AKORN INC (AKRX)

akorn inc (AKRX) Related Businessweek News

No Related Businessweek News Found

akorn inc (AKRX) Details

Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and other eye health products under the TheraTears name through chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. This segment offers ophthalmic products, such as AzaSite, an azithromycin ophthalmic solution; Cosopt, a dorzolamide hydrochloride and timolol maleate ophthalmic solution; and Cosopt PF, a preservative-free prescription version of Cosopt. The Hospital Drugs & Injectables segment provides hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. The Contract Services segment manufactures various pharmaceutical products for third party pharmaceutical customers based on their specifications. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.

1,099 Employees
Last Reported Date: 03/14/14
Founded in 1971

akorn inc (AKRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $250.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $309.0K
Chief Operating Officer
Total Annual Compensation: $313.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $286.3K
Senior Vice President of National Accounts an...
Total Annual Compensation: $280.2K
Compensation as of Fiscal Year 2013.

akorn inc (AKRX) Key Developments

Akorn, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 09:30 AM

Akorn, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 09:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Timothy A. Dick, Chief Financial Officer and Principal Accounting Officer.

Akorn, Inc., VPI Holdings Corp. - M&A Call

To discuss the acquisition of Akorn and VPI Holdings Corp

Akorn, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Full Year 2014

Akorn, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company's revenue was $90,622,000, an increase of 23% over the first quarter 2013 consolidated revenue of $73,854,000. The increase in consolidated revenue was largely driven by the newly acquired branded ophthalmic products-Azasite(R), Cosopt(R), CosoptPF(R), and Betimol(R). Net income for the first quarter of 2014 was $9,828,000 or $0.08 per diluted share, compared to net income of $10,842,000 or $0.10 per diluted share, in the prior year quarter. First quarter 2014 net income included $6.4 million of acquisition-related expenses, the component of which was fees incurred pre-close on the Hi-Tech term loan commitments. Non-GAAP adjusted net income for the first quarter of 2014 was $18,386,000 or $0.16 per diluted share, compared to non-GAAP adjusted net income of $14,437,000 or $0.13 per diluted share, in the prior year quarter. Operating income was $23,440,000 against $18,589,000 a year ago. Income before income taxes was $15,692,000 against $16,257,000 a year ago. Net cash provided by operating activities was $23,376,000 against $6,922,000 a year ago. Purchases of property, plant and equipment was $5,198,000 against $2,689,000 a year ago. EBITDA was $24,528,000 against $21,750,000 a year ago. Adjusted EBITDA was $31,839,000 against $24,497,000 a year ago. Adjusted income before income taxes was $29,009,000 against $21,963,000 a year ago. For the full year 2014, the company’s expects GAAP net income to be $51 million to $53 million. Intangible asset amortization expense to be $33 million. Adjusted net income to be $94 million to $97 million. Adjusted net income per diluted share to be $0.79 to $0.82. Depreciation and amortization expense to be $45 million. Interest expense, net (cash & non-cash) to be $27 million. EBITDA to be $153 million to $156 million. Adjusted EBITDA to be $183 million to $188 million. Total revenues to be $540 million - $560 million. Total gross margin percentage to be 52% to 54%. Intangible asset amortization expense to be $33 million. Income tax rate to be 37%. GAAP net income per diluted share to be $0.43 to $0.45. Capital expenditures to be $45 million to $55 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKRX:US $34.12 USD +1.01

AKRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $8.69 USD -0.36
Impax Laboratories Inc $28.92 USD -0.40
Lannett Co Inc $46.27 USD -0.38
Pfizer Ltd/India 1,365 INR +0.60
Sagent Pharmaceuticals Inc $26.24 USD -0.05
View Industry Companies
 

Industry Analysis

AKRX

Industry Average

Valuation AKRX Industry Range
Price/Earnings 74.3x
Price/Sales 9.6x
Price/Book 11.7x
Price/Cash Flow 55.7x
TEV/Sales 9.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKORN INC, please visit www.akorn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.